ZLDI-8, a novel inhibitor of ADAM17, has been reported to inhibit the Notch pathway and reverse the EMT process, thereby inhibiting migration and invasion in chemotherapy-resistant NSCLC.354 Notch1 induces EMT and chemoresistance in TNBC cells by directly activating the MCAM promoter. The gene discussed is NOTCH1; the disease is non-small cell lung carcinoma.